PYXS Pyxis Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PYXS

Price (delayed)

$1.73

Market cap

$109.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$120.62M

?
Relative Growth: Rel. Growth: 7
Relative Strength: Rel. Strength: 50
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 26

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype ...

Highlights
Pyxis Oncology's debt has decreased by 8% YoY and by 2.2% QoQ
PYXS's EPS is up by 17% year-on-year but it is down by 2.3% since the previous quarter
Pyxis Oncology's net income has increased by 14% YoY but it has decreased by 2.7% QoQ
The equity has plunged by 70% YoY and by 41% from the previous quarter
PYXS's quick ratio has dropped by 65% year-on-year and by 20% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.pyxisoncology.com
Peers: ONC MRNA NVAX INO

Key stats

What are the main financial stats of PYXS

PYXS stock price

How has the Pyxis Oncology stock price performed over time
Intraday
1.76%
1 week
-2.81%
1 month
-1.7%
1 year
35.16%
YTD
50.43%
QTD
18.49%

Financial performance

How have Pyxis Oncology's revenue and profit performed over time
Revenue
$13.86M
Gross profit
$11.47M
Operating income
-$85.87M
Net income
-$81.74M
Gross margin
82.8%
Net margin
-589.8%
The operating income has increased by 20% YoY
Pyxis Oncology's net income has increased by 14% YoY but it has decreased by 2.7% QoQ
Pyxis Oncology's net margin has decreased by 2.7% QoQ

Price vs fundamentals

How does PYXS's price correlate with its fundamentals

Growth

What is Pyxis Oncology's growth rate over time

Valuation

What is Pyxis Oncology stock price valuation
P/E
N/A
P/B
3.48
P/S
7.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.7
PYXS's EPS is up by 17% year-on-year but it is down by 2.3% since the previous quarter
PYXS's P/B is 90% above its last 4 quarters average of 1.8
The equity has plunged by 70% YoY and by 41% from the previous quarter
PYXS's P/S is 63% below its last 4 quarters average of 21.3

Efficiency

How efficient is Pyxis Oncology business performance
The return on equity has dropped by 95% year-on-year and by 33% since the previous quarter
Pyxis Oncology's ROA has plunged by 55% YoY and by 22% from the previous quarter
The ROIC has decreased by 44% YoY and by 23% from the previous quarter
PYXS's return on sales is down by 2.7% since the previous quarter

Dividends

What is PYXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PYXS.

Financial health

How did Pyxis Oncology financials performed over time
The company's total assets is 95% higher than its total liabilities
PYXS's quick ratio has dropped by 65% year-on-year and by 20% since the previous quarter
PYXS's current ratio has dropped by 64% year-on-year and by 19% since the previous quarter
Pyxis Oncology's debt is 42% lower than its equity
The equity has plunged by 70% YoY and by 41% from the previous quarter
The debt to equity has surged by 66% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.